Considerations for monkeypox vaccination
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All
Filetype[PDF-962.45 KB]


  • English

  • Details:

    • Description:
      What You Need to Know • Two vaccines licensed by the U.S. Food and Drug Administration (FDA) are available for preventing monkeypox infection – JYNNEOS (also known as Imvamune or Imvanex) and ACAM2000. • In the United States, there is currently a limited supply of JYNNEOS, although more is expected in coming weeks and months. • There is an ample supply of ACAM2000. However, this vaccine should not be used in people who have some health conditions, including a weakened immune system, skin conditions like atopic dermatitis/eczema, or pregnancy. • No data are available yet on the effectiveness of these vaccines in the current outbreak. • People are considered fully vaccinated about 2 weeks after their second shot of JYNNEOS and 4 weeks after receiving ACAM2000. However, people who get vaccinated should continue to take steps to protect themselves from infection by avoiding close, skin-to-skin contact, including intimate contact, with someone who has monkeypox. • To better understand the protective benefits of these vaccines in the current outbreak, CDC will collect data on any side effects and whether the way the person was infected makes any difference in how well the vaccine protects them.
    • Content Notes:
      What You Need to Know -- Vaccine Strategies to Prevent Monkeypox -- Vaccine Information (JYNNEOS and ACAM2000) -- Planning Considerations for Health Departments and Providers -- Resources.
    • Document Type:
    • Genre:
    • Place as Subject:
    • Main Document Checksum:
    • File Type:

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov